July 11, 2007 - RNAi deals continue at torrid pace! : Lhe last significant player in RNA interference, Alnylam Pharmaceuticals Inc., is now off the partnering trail. Just inked a non-exclusive licensing d
More News
July 9, 2007 - Silence signs a $400M deal with Astrazeneca for RNAi tech for respiratory diseases. : RNAi firm Silence Therapeutics plc signed a deal with AstraZeneca for a potential £200 million (US$400 million) to develop drugs against respiratory d
More News
July 5, 2007 - Intercell Ag rise to a market cap of close to 1 US$ Billion on news of pact with Novartis. : Intercell gained 15%, bringing its market cap close to 1 US$ Billion, on news of broad alliance with Novartis AG.Intercell gets €270 million (US$366.7
More News
July 4, 2007 – Genzyme offers $345M for clofarabine partner Bioenvision Inc. in a stock deal. : Bioenvision sells clofarabine (Evoltra) in Europe for pediatric relapsed or refractory pediatric acute lymphoblastic leukemia. Genzyme gained North Am
More News
July 4, 2007 – Japanese & US scientists isolated cells with epigenetic features of embryonic stem cells from induced pluripotent cells ( iPC) drived from skin fibroblasts. : iPCs are obtained by Induction of expression of four genes. They are quasi-embryonic stem cells which however lack epigenetic DNA methylation patterns
More News
July 4, 2007 - 2 Amgen buys in a week: Ilypsa for $420M and Alantos for $300M Cash : Ilypsa brings to Amgen a Phase II phosphate binder for chronic kidney disease. Will compete with Genzyme’s Renvela. Alantos brings to Amgen a DPP-I
More News
July 4, 2007 – ZymoGenetics & Bayer in a $200M deal over hr Thrombin : Bayer acquired acquired rights outside the U.S. to hr Thrombin in exchange for $30 million up front and another $40 million upon FDA approval + 130 mi
More News
July 4, 2007 - Renovo Group plc & Shire in $800M + deal for anti-scarring drug. : Juvista is an injection of hrTransforming Growth Factor beta3 (TGF-beta3), a protein present in high levels in developing embryonic skin and in embryo
More News
July 3, 2007 – Biogen & Cardiokine in $220Mio deal for vasopressin receptor antagonist lixivaptan. : Cardiokine Inc gets $50 million up front in a $220 million deal with Biogen Idec Inc. for vasopressin receptor antagonist lixivaptan. The oral agent
More News
EU FP7: next call due on September 18 : The next call deadline for Theme 1 (Health) is September 18. We are selecting projects to partner with. Inquiries: fp7@bioinnovit.com
More News
May 31, 2007 – Novacea & ScheringPlough Corp. in a $380M licensing deal. : Novacea licensed late-stage prostate cancer drug, Asentar to ScheringPlough Corp. for $60 million up front and the potential for $380 million in miles
More News
EU FP7: next call due on September 18 : The next call deadline for Theme 1 (Health) is September 18. We are selecting projects to partner with. Inquiries: fp7@bioinnovit.com
More News
June 4, 2007 – Jazz Pharmaceuticals raises $108M in IPO : Jazz Pharmaceuticals raises $108M in IPO to launch Luvox, CR for psychiatric disorders and advance the pipeline. Luvox CR was deemed approvable in Fe
More News
More News
